

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2016/03/31	2015/12/31	2015/03/31
Balance Sheet			
Current assets			
Total cash and cash equivalents	458,006	305,619	1,176,332
Total Current investments in debt instrument without active market	610,826	859,867	150,000
Notes receivable due from related parties, net	0	71	0
Accounts receivable, net	5,575	18,570	10,524
Accounts receivable due from related parties, net	30	0	60
Other receivables, net	12,380	2,892	8,937
Other receivables due from related parties, net	0	0	0
Total current tax assets	4,212	4,038	3,186
Total inventories	24,433	22,627	18,568
Total prepayments	33,833	21,576	12,113
Total other current assets	10,031	9,323	1,414
Total current assets	1,159,326	1,244,583	1,381,134
Non-current assets			
Total Non-current investments in debt instrument without active market	30,000	30,000	30,000
Total property, plant and equipment	216,570	199,876	188,108
Total intangible assets	368	580	1,517
Deferred tax assets	39,672	40,173	40,137
Total other non-current assets	16,019	3,174	8,736
Total non-current assets	302,629	273,803	268,498
Total assets	1,461,955	1,518,386	1,649,632
Current liabilities			
Total notes payable	0	0	0
Total accounts payable	17,785	19,619	7,331
Total accounts payable to related parties	0	40	0
Total other payables	24,287	30,362	21,994
Total other current liabilities	20,902	11,618	15,695
Total current liabilities	62,974	61,639	45,020
Non-current liabilities			
Total deferred tax liabilities	360	796	0
Total other non-current liabilities	1,729	1,737	3,006
Total non-current liabilities	2,089	2,533	3,006
Total liabilities	65,063	64,172	48,026
Share capital			
Ordinary share	1,117,150	1,115,990	1,110,145
Advance receipts for share capital	1,983	2,211	1,092
Total share capital	1,119,133	1,118,201	1,111,237
Capital surplus			
Total capital surplus, additional paid-in capital	616,540	614,631	603,814
Capital surplus, treasury share transactions	2,812	2,812	2,812
Capital surplus, employee share options	3,613	3,876	8,746
Total capital surplus	622,965	621,319	615,372
Retained earnings			
Total unappropriated retained earnings (accumulated deficit)	-257,595	-197,695	-125,003
Total retained earnings	-257,595	-197,695	-125,003
Other equity interest			
Total other equity, others	0	0	0
Total other equity interest	0	0	0
Treasury shares	-87,611	-87,611	0
Total equity	1,396,892	1,454,214	1,601,606
Total liabilities and equity	1,461,955	1,518,386	1,649,632
Number of share capital awaiting retirement	0	0	0
Equivalent issue shares of advance receipts for ordinary share	103,000	116,000	58,500
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	0

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2016/01/01To2016/03/31	2015/01/01To2015/03/31
Income Statement		
Total operating revenue	9,969	11,985
Total operating costs	30,657	15,793
Gross profit (loss) from operations	-20,688	-3,808
Gross profit (loss) from operations	-20,688	-3,808
Operating expenses		
Total selling expenses	2,085	587
Total administrative expenses	7,078	6,618
Total research and development expenses	41,076	32,430
Total operating expenses	50,239	39,635
Net operating income (loss)	-70,927	-43,443
Non-operating income and expenses		
Total other income	13,371	10,772
Other gains and losses, net	-2,279	-4,310
Total non-operating income and expenses	11,092	6,462
Profit (loss) from continuing operations before tax	-59,835	-36,981
Total tax expense (income)	65	87
Profit (loss) from continuing operations	-59,900	-37,068
Profit (loss)	-59,900	-37,068
Total comprehensive income	-59,900	-37,068
Basic earnings per share		
Total basic earnings per share	-0.55	-0.33

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2016/01/01To2016/03/31	2015/01/01To2015/03/31
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-59,835	-36,981
Profit (loss) before tax	-59,835	-36,981
Depreciation expense	9,454	8,368
Amortization expense	212	345
Provision (reversal of provision) for bad debt expense	3	0
Interest income	-2,452	-5,026
Share-based payments	595	476
Impairment loss on non-financial assets	22	74
Other adjustments to reconcile profit (loss)	0	0
Total adjustments to reconcile profit (loss)	7,834	4,237
Decrease (increase) in notes receivable due from related parties	71	0
Decrease (increase) in accounts receivable	12,992	29,629
Decrease (increase) in accounts receivable due from related parties	-30	4,867
Decrease (increase) in other receivable	-9,654	-1,245
Decrease (increase) in other receivable due from related parties	0	0
Decrease (increase) in inventories	-1,828	-3,677
Decrease (increase) in prepayments	-12,257	454
Decrease (increase) in other current assets	-708	-512
Total changes in operating assets	-11,414	29,516
Increase (decrease) in notes payable	0	0
Increase (decrease) in accounts payable	-1,834	-4,102
Increase (decrease) in accounts payable to related parties	-40	-23
Increase (decrease) in other payable	-10,917	-10,013
Increase (decrease) in other current liabilities	9,284	282
Increase (decrease) in net defined benefit liability	-8	40
Total changes in operating liabilities	-3,515	-13,816
Total changes in operating assets and liabilities	-14,929	15,700
Total adjustments	-7,095	19,937
Cash inflow (outflow) generated from operations	-66,930	-17,044
Income taxes refund (paid)	-174	-457
Net cash flows from (used in) operating activities	-67,104	-17,501
Cash flows from (used in) investing activities		
Acquisition of investments in debt instrument without active market	-72,668	-30,000
Proceeds from disposal of investments in debt instrument without active market	321,709	1,005,749
Acquisition of property, plant and equipment	-21,243	-25,539
Increase in refundable deposits	-171	-124
Acquisition of intangible assets	0	0
Increase in prepayments for business facilities	-12,737	-1,596
Interest received	2,618	5,397
Net cash flows from (used in) investing activities	217,508	953,887
Cash flows from (used in) financing activities		
Exercise of employee share options	1,983	1,092
Net cash flows from (used in) financing activities	1,983	1,092
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	152,387	937,478
Cash and cash equivalents at beginning of period	305,619	238,854
Cash and cash equivalents at end of period	458,006	1,176,332
Cash and cash equivalents reported in the statement of financial position	458,006	1,176,332
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

